Abivax Banks €130m To Advance Obefazimod
In Phase III For Ulcerative Colitis
The French biotech has attracted a raft of new US healthcare specialist backers in one of the biggest raises ever on the Euronext Paris but it will need millions more to complete the late-stage program for obefazimod.
